The human tumor phenotype referred to as MSI arises because of defects in the DNA mismatch repair (MMR) system [1] [2] [3] . MSI was first observed in inherited tumors associated with Lynch syndrome (heredi tary nonpolyposis colorectal cancer) and later in sporadic colon, gas tric and endometrial cancers (for a review, see ref. 4 ). The normal function of the MMR system is to recognize and repair the errors that arise during DNA replication, as well as to repair some forms of DNA damage. It is now well established that MMR deficiency is not in itself a direct transforming event and that MSI tumors develop through a distinctive molecular pathway characterized by the genetic instability of numerous microsatellite repeat sequences throughout the genome 4 . Most oncogenic alterations found in MSI tumors are thus somatic mutational events that affect coding repeated sequences. The major ity of published articles on the mechanisms underlying MSI carcino genesis have involved the study of CRC. These revealed that MSI CRCs is a distinctive group from the major tumor type called chromosomal instability (CIN) or microsatellite stable (MSS) (for review, see ref. 5 ). In addition to the genetic instability in coding repeats, MSI tumor cells accumulate hundreds of alterations in noncoding microsatellite repeats throughout the genome 6 , but the functional consequences of these mutations have yet to be thoroughly investigated.
Although MSI cancers are considered to represent a distinct tumor entity, there is still no specific therapeutic approach that takes into account the unique mode of cell transformation seen within these tumors. MSI CRCs have been consistently reported to show an improved prognosis and a different response to chemo therapeutic agents 7, 8 . The reasons underlying these clinical observations are still poorly understood. Here we identified HSP110 as a target gene for mutation in MSI CRCs. HSP110 is a conserved and abundant molecular chaperone whose expression is induced by a specific set of stress conditions. HSP110 accumu lates abnormally in cancer cells, and this is believed to enhance Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110DE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110DE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110DE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorouracil, which are routinely prescribed in the adjuvant treatment of people with CRC. The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110DE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC. a r t i c l e s 1 2 8 4 VOLUME 17 | NUMBER 10 | OCTOBER 2011 nature medicine their survival [9] [10] [11] [12] . It is strongly expressed in colon cancer cells 13 , and gene expression profile analysis of primary CRC has linked HSP110 expression with metastasis and poor prognosis 14 .
We show in this work that a T 17 mononucleotide repeat located in intron 8 of HSP110 was systematically mutated in MSI CRC cell lines and primary tumors. The shortening of this repeat in tumor DNA cor related with increased synthesis of an aberrant HSP110 transcript due to exon 9 skipping, to the detriment of wildtype HSP110 mRNA. The mutant transcript encoded a truncated isoform of HSP110, referred to as HSP110∆E9. The overexpression of HSP110∆E9 in CRC cells severely affected the function of HSP110 chaperone in a dosedependent manner. HSP110∆E9 expression also increased the sensitivity to anti cancer agents such as oxaliplatin and 5fluorouracil (5FU), which are routinely prescribed in the adjuvant treatment of CRC patients. In agreement with these in vitro findings, the survival of people with MSI CRC was associated with the tumor expression level of HSP110∆E9.
RESULTS

HSP110 T 17 intronic DNA microsatellite mutations in MSI CRC
To find new mutations with a putative role in MSIdriven carcino genesis, we analyzed the expression pattern of 45 candidate exons located downstream of an intron containing a mononucleotide repeat sequence of at least eight nucleotides in the vicinity of the splice acceptor site (Supplementary Table 1 and Fig. 1a) . The search was undertaken by nonquantitative RTPCR using a set of human MSI and MSS CRC cell lines (n = 20; 13 MSI, 7 MSS). A total of 43 exons were found to have the same expression pattern in MSI and MSS cancer cell lines (Fig. 1a) . In the remaining two cases (MRE11 (current symbol MRE11A) and HSP110), the presence of an addi tional PCR product was only detectable in MSI CRC cell lines. This was due to exon 5 skipping in MRE11 (data not shown), as reported elsewhere 6 , and exon 9 skipping in HSP110 (Fig. 1b and data not  shown) . We found the presence of this additional HSP110 RTPCR product to be specific to MSI primary colorectal tumor samples (Fig. 1b) . We did not detect it in a series of nontumor human cell lines used as additional MMRproficient controls (lymphoblastoid cell lines, LBLs; n = 20) (Fig. 1b) . Among subjects with primary MSI CRC, amplification of the additional RTPCR product was restricted to MSI tumor tissues and was never observed in matching normal mucosal samples (Fig. 1b) .
Next, we determined the mutational status of the HSP110 T 17 DNA repeat located upstream and near the splice acceptor site in intron 8 ( Supplementary Fig. 1 ). Allelic profiles of this noncoding repeat were analyzed using fluorescence genotyping in our panel of MSI and MSS CRC cell lines and primary tumors, as well as in control LBLs to assess its polymorphic status (Supplementary Table 2 ). Overall, we found that this sequence was weakly polymorphic in MMRproficient samples (Fig. 1c) , whereas it was systematically mutated in 13 of 13 (100%) MSI CRC cell lines and in 43 of 43 (100%) MSI CRC primary tumors. The allelic deletions ranged from three to eight base pairs beyond the polymorphic zone ( Fig. 1c and Supplementary Table 2) . The mutation frequency of HSP110 T 17 was higher than that of all coding microsatellite targets reported to date in MSI primary CRC (Fig. 1d) . We also detected this mutation in 9 of 17 (53%) adenomas with MSI, although with smaller allelic deletions than observed for MSI primary CRCs (Fig. 1d) .
Overexpression of HSP110 mRNA lacking exon 9 in MSI CRC We first confirmed by quantitative RTPCR that the two HSP110 PCR products observed in MSI cancer cell lines corresponded to HSP110 alternative mRNAs that contained or lacked exon 9 (Fig. 2a) . We quanti fied both HSP110 mRNA containing (HSP110wt) or lacking exon 9 (HSP110∆E9) in a competitive manner (Supplementary Table 2) . We observed that HSP110∆E9 mRNA was weakly expressed in MSS CRC cell lines (below 5-10% of HSP110wt mRNA; Fig. 2b ). In contrast, HSP110∆E9 mRNA expression was higher in MSI CRC cell lines and was significantly different between MSI (n = 43) and MSS (n = 20) primary CRCs (P = 8.5 × 10 -5 ; Fig. 2b and Supplementary Table 2 ). We next investigated whether mutation of the HSP110 T 17 intronic DNA repeat might influence the expression of HSP110 in our series of primary CRCs. We found that the length of T 17 deletion was associ ated with significantly increased expression of HSP110∆E9 mRNA, to the detriment of the HSP110wt transcript ( Fig. 2c ; P = 1.1 × 10 −13 ). HSP110∆E9 mRNA was generally expressed at low levels in MSI tumors showing small T 17 deletions (3 or 4 bp; Fig. 2c ), or in MSS tumors that were not mutated. In contrast, it was highly expressed in MSI tumors with larger T 17 deletions (from 5 to 8 bp; Fig. 2c ). We confirmed these results at the protein level using western blotting in 10 MSI primary CRCs that showed variable allelic shifts in the T 17 repeat ( Fig. 2d ; P < 0.05). We concluded that mutation of the HSP110 intronic T 17 microsatellite was probably the causative event leading to aberrant expression of this chaperone in colorectal tumors.
Altered HSP110∆E9 chaperone sensitizes cancer cells to die
The skipping of HSP110 exon 9 causes a frameshift that leads to the generation of a premature termination codon in exon 10 of HSP110∆E9 mRNA (Supplementary Fig. 1 ). HSP110∆E9 is a trun cated protein that contains the Nterminal ATPbinding domain but is devoid of the substratebinding domain ( Supplementary Fig. 1 ). We used several functional assays to understand the role of HSP110∆E9. We first studied its chaperone activity using a protein thermolability assay that measures the in vitro ability of HSP110 to block protein aggregation induced by a heat shock. Although HSP110wt showed antiaggregation activity comparable to other HSPs such as HSP70, HSP110∆E9 did not demonstrate this chaperone activity (Fig. 3a) . Interestingly, this effect was dominant negative, because the antiaggre gation activity of HSP110wt was abrogated if HSP110∆E9 was added (Fig. 3a) . HSP110 has been shown to associate with other chaperones such as HSP70, and this contributes to the overall cell chaperone net work. We confirmed here in HCT116 cells that HSP110wt efficiently interacted with HSP70 and with HSP27, but not with HSP90 (Fig. 3b) . In contrast, HSP110∆E9 lost the ability to associate with HSP70 and HSP27 (Fig. 3b ) but associated strongly with HSP110wt, in line with its dominantnegative effect (Fig. 3c) . Finally, HSP110∆E9 showed an altered cellular localization compared to HSP110wt. Although we found the latter both in the nucleus and cytosol, HSP110∆E9 was restricted to the cytosol (Fig. 3d) . Further, HSP110∆E9 was able to block HSP110 translocation into the nucleus (Fig. 3e) .
In a xenograft mouse model, HSP110∆E9 expression significantly decreased the tumorigenicity of HCT116 cells (Fig. 4a) . Because the role of HSPs including HSP110 in cancer has been linked to their antiapoptotic properties, we investigated the effect on apoptosis of the HSP110 truncation. HCT116, LoVo (MSI) and SW480 (MSS) cells were transfected with HSP110wt or HSP110∆E9, and apoptosis was triggered using TRAIL (tumor necrosis factor-related apoptosis inducing ligand). As expected, TRAIL induced dosedependent apoptosis and HSP110wt exerted a protective effect, as demon strated by the appearance of wellknown apoptotic markers including caspase 8 cleavage, caspase 3 activity, cleavage of the caspase 3 target PARP, mitochondrial membrane permeation and nuclear condensa tion (Fig. 4b-d and Supplementary Fig. 2 ). In contrast, HSP110∆E9 not only lacked the protective properties of HSP110wt but was also able to block its antiapoptotic function in a dosedependent manner (Fig. 4c-e) . Probably as a consequence, the overexpression of HSP110∆E9 in various CRC cell lines (both MSI and MSS) increased their sensitivity to anticancer agents such as oxaliplatin and 5FU, two drugs commonly used in the adjuvant treatment of CRC patients (Fig. 4f, Supplementary Fig. 3 and data not shown).
HSP110∆E9 affects survival and response to chemotherapy
We next investigated the possible clinical relevance of HSP110∆E9 by evaluating the expression of HSP110∆E9 mRNA relative to HSP110wt Fig. 4) . Using a HSP110∆E9/HSP110wt mRNA ratio of 75%, MSIHSP110∆E9 high subjects showed diseasefree survival (DFS) and response to chemotherapy that differed from those of MSIHSP110∆E9 low subjects. The difference in DFS approached significance for persons with stage 3 MSI CRC and for people who received adjuvant chemotherapy but not for those with stage 2 MSI CRC (Supplementary Fig. 5 ).
To validate the above clinical findings, we did similar analysis on an independent series of subjects with MSI CRC (n = 54; 30 stage 2 and 24 stage 3; Supplementary Table 3) . Here again, a closely related HSP110∆E9/HSP110wt mRNA ratio (50%) revealed the clinical impact of the HSP110 mutant on survival and response to chemo therapy. This impact was substantial for persons with stage 3 CRC and for people who received adjuvant chemotherapy ( Supplementary  Fig. 5 ). The two subject series were combined to obtain greater sta tistical power. However, significant results were also obtained for subjects with stage 3 MSI CRC when the cutoff point correspond ing to 75% was used for both series, after necessary normalization of the HSP110∆E9/HSP110wt ratio for the two series (P = 0.042, N HSP110∆E9high = 7, N HSP110∆E9low = 18; data not shown). In the over all series, the survival and response to chemotherapy of persons with stage 3 MSI CRC were confirmed in univariate analyses to be asso ciated with the tumor expression level of HSP110∆E9 (Fig. 5 and Table 1 ). In multivariate analysis, HSP110∆E9 was found to be an independent predictor of outcome in persons with MSI CRC (Table 1  and Supplementary Table 4) .
DISCUSSION
Like other stressinducible HSPs, HSP110 protects the cell against adverse conditions. HSP110 also provides specific crucial functions, as hsp110 gene knockout in both yeast and Drosophila is lethal 15 . Two different isoforms of HSP110 have been described, HSP110a and HSP110b, but their different functions in the cell, if any, are unknown. HSP110b results from alternative splicing of exon 12 and lacks 43 amino acids from the Cterminal part of HSP110a. Notably, HSP110a and HSP110b isoforms are irrelevant to generation of the truncated HSP110∆E9 form identified here due to exon 9 skipping. HSP110 not only acts as a nucleotide exchange factor for HSP70 (ref. 18, 19 . HSP110 chaperone activity is independent of ATP but requires the substratebinding domain of the protein. HSP110∆E9 lacks the substratebinding domain. As a consequence, it has lost its HSP110 antiaggregation chaperone function and is unable to bind HSP70, thereby also losing its function as a nucleotide exchange factor for HSP70 proteins. A possible explanation for HSP110 overexpression in CRC cells 13 is that they must extensively rewire their metabolic and signal transduction pathways, thereby becoming dependent on proteins that are dispensable for the survival of normal cells. The tumori genic properties of HSP110, although not fully understood, may in part be explained by its antiapoptotic properties 20, 21 . Overexpression of HSP110 has been shown to protect against apoptotic cell death in different cellular models including colon cancer. Inversely, small interfering RNA-mediated depletion of HSP110 induces apoptosis in HCT116 cells 10 . Interestingly, we showed in this work that a similar induction of apoptosis in HCT116 cells was achieved by overexpres sion of the mutant HSP110∆E9. We found that significant expression of HSP110∆E9 was restricted to colon cancer cells with MSI, thus disadvantaging their survival. Indeed, HSP110∆E9 has not only lost the normal HSP110 antiapoptotic properties but also associates with HSP110 to block these protective functions in a dosedependent man ner. Further, when overexpressed in both MSI and MSS CRC cells, HSP110∆E9 sensitizes these cells to apoptosis induced by chemo therapeutic drugs. It is worth noting that these proapoptotic effects are optimized when HSP110∆E9 expression is similar to or higher than that of HSP110wt. This probably occurs because each molecule of HSP110∆E9 forms a complex with one molecule of HSP110wt, thus neutralizing its function. It is unclear why there is selection of the HSP110∆E9 dominant negative and proapoptotic mutant in MSI CRCs. A possible explanation is that long, noncoding mononucleotide repeats such as the T 17 located in HSP110 intron 8 are often hot spots for mutations in MSI tumors due to the MMR deficiency 22, 23 . Whereas most of these microsatellites are function ally anonymous, a few are endowed with biological activity. Even though they result in a tumor suppressor effect, frequent muta tion of these sequences can occur, as shown in the current work, thus representing the Achilles' heel of the MSIdriven tumorigenic process. Mutation of HSP110 T 17 is detected in 53% of MSI adenomas-a frequency that is comparable to mutation to TGFBR2 and is an early event in the MSIdriven pathway to cancer 24 . Nevertheless, these alterations fre quently consist of small allelic deletions that may have little effect on HSP110∆E9 expres sion in these premalignant tumors. In con trast, all MSI tumors were mutated at T 17 and showed accumulation of HSP110∆E9 at vari able levels. Although HSP110 T 17 mutation is an early event, it may therefore impact upon HSP110 function in only a few adenomas. Our hypothesis is that it acts as an anticancer event at a later stage in the progression of MSI color ectal tumors. Those with high expression of HSP110∆E9 mRNA represent about 30-40% of all subjects with MSI colon tumors. The closely related HSP110∆E9/HSP110wt mRNA ratios of 75% and 50% were chosen in the two independent series we analyzed, as they maximized the difference in survival between subjects with MSIHSP110∆E9 high and MSI HSP110∆E9 low . In line with our in vitro tran sient experiments that showed a progressive and dosedependent proapoptotic effect of HSP110∆E9 in CRC cells, the 'protective' clin ical effect of HSP110∆E9 is also expected to be progressive and dose dependent, so that the choice of a cutoff point, whatever its threshold, is somewhat artificial. Under these conditions, subjects with MSIHSP110∆E9 high stage 3 CRC showed excellent survival and response to chemotherapy. This was not observed for subjects with stage 2 MSI CRC, however, presumably because of the low frequency of disease recurrence in this group. Overall, our results are suggestive of clinical heterogeneity in people with MSI CRC due to a dosedependent effect of tumor HSP110∆E9 expression. Because this mutant protein is expressed at variable levels in almost all MSI CRCs, it is likely to constitute a crucial determinant Subjects from both series were combined using series-specific cutoff points to define HSP110∆E9 expression classes (75% and 50% for first and second series, respectively). of prognosis and treatment response in these tumors. We defined a subgroup of subjects with MSIHSP110∆E9 high that represented approximately one third of all subjects with MSI CRC and who showed excellent survival and response to chemotherapy. A key question will be to determine whether distinct therapeutic protocols could be pro posed for persons with MSI CRC showing high or low expression of HSP110∆E9. In our cohort it was not possible to look separately at those who received 5FU alone, as most subjects received a combina tional therapy. Because subjects with MSIHSP110∆E9 high represent only a small fraction of persons with MSI CRC, these data do not contradict previous results demonstrating that, overall, subjects with MMRdeficient CRC have a worse response to 5FU than those with MMRproficient CRC. They are suggestive of clinical heterogeneity in the group of people with MSI regarding response to this drug. We anticipate that HSP110∆E9 should also show aberrant expres sion in MSI cancers from other primary locations such as stomach, endometrium and other more recently reported sites 25 . The target ing of HSPs has also emerged as an interesting sensitization strategy in cancer therapy. Different inhibitors of HSP90, HSP27 and HSP70 (ref. 26 ) are currently being evaluated in persons with cancer, with some already in phase 2 or 3 clinical trials 27 . Interestingly, the present work is the first report to our knowledge of an HSP inhibitor that is produced endogenously by the cell. In the future, designing small peptides that mimic the sensitizing function of HSP110∆E9 and could therefore be readily adapted to improve the treatment of both MSI and MSS tumors may constitute viable therapeutic strategies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
